Display options
Cite
Eshraghi Samani R, Shirkhoda M, Hadji M, et al. The prognostic value of lymph node ratio in survival of head-and-neck squamous cell carcinoma. J Res Med Sci. 2018;23:35doi: 10.4103/jrms.JRMS_948_17.
Eshraghi Samani, R., Shirkhoda, M., Hadji, M., Beheshtifard, F., Hamedani, S. M. M. G., Momen, A., Mollashahi, M., & Zendehdel, K. (2018). The prognostic value of lymph node ratio in survival of head-and-neck squamous cell carcinoma. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2335. https://doi.org/10.4103/jrms.JRMS_948_17
Eshraghi Samani, Reza, et al. "The prognostic value of lymph node ratio in survival of head-and-neck squamous cell carcinoma." Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences vol. 23 (2018): 35. doi: https://doi.org/10.4103/jrms.JRMS_948_17
Eshraghi Samani R, Shirkhoda M, Hadji M, Beheshtifard F, Hamedani SMMG, Momen A, Mollashahi M, Zendehdel K. The prognostic value of lymph node ratio in survival of head-and-neck squamous cell carcinoma. J Res Med Sci. 2018 Apr 26;23:35. doi: 10.4103/jrms.JRMS_948_17. eCollection 2018. PMID: 29887903; PMCID: PMC5961280.
Copy Download .nbib Format: NLM
Share it on

J Res Med Sci. 2018 Apr 26;23:35. doi: 10.4103/jrms.JRMS_948_17. eCollection 2018.

The prognostic value of lymph node ratio in survival of head-and-neck squamous cell carcinoma.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

Reza Eshraghi Samani, Mohammad Shirkhoda, Maryam Hadji, Faramarz Beheshtifard, Seyed Mohammad Mehdi Ghaffari Hamedani, Ali Momen, Mahtab Mollashahi, Kazem Zendehdel

Affiliations

  1. Department of Surgery, Isfahan University of Medical Sciences, Isfahan, Iran.
  2. Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran, Iran.
  3. Department of Surgery, Mazandaran University of Medical Sciences, Mazandaran, Iran.
  4. Resident of General Surgery, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 29887903 PMCID: PMC5961280 DOI: 10.4103/jrms.JRMS_948_17

Abstract

BACKGROUND: Head-and-neck squamous cell carcinoma (HNSCC) is the sixth most prevalent type of cancers in the world. Due to its relatively high rate of recurrence, the prognosis of patients is poor and the survival rate is low; therefore, identifying the prognostic factors is considered necessary for better treatment.

MATERIALS AND METHODS: This historical cohort study was conducted on 201 patients diagnosed with aerodigestive SCC who underwent surgery and lymph node dissection. We determined the prognostic value of lymph node ratio (LNR) on overall survival (OS), disease-free survival (DFS), and locoregional failure-free survival (LFFS). We noticed an association between LNR and survival by Kaplan-Meier analysis. Hazard ratio (HR) of LNR was determined by Cox's regression model.

RESULTS: Two hundred and one patients entered this study after their medical histories were evaluated. The mean of lymph node count and LNR was 14.30 (±9.50) and 0.12 (±0.23), respectively. Eighty patients (39.80%) experienced recurrence of SCC. Five-year OS, DFS, and LFFS were 32%, 21%, and 64%, respectively. The median of OS was 40.70 months and 30.11 months in patients with LNR of ≤0.06 and >0.06, respectively (

CONCLUSION: We recommend more intensive adjuvant therapies such as chemotherapy with radiotherapy and short interval follow-up for patients with LNR >0.06. Further investigations with larger sample sizes are recommended.

Keywords: Head-and-neck squamous cell carcinoma; lymph node ratio; survival

Conflict of interest statement

There are no conflicts of interest.

References

  1. Acta Otorhinolaryngol Ital. 2017 Dec;37(6):458-466 - PubMed
  2. J Surg Oncol. 2013 Sep;108(4):256-63 - PubMed
  3. Br J Cancer. 2010 Aug 24;103(5):613-6 - PubMed
  4. J Otolaryngol Head Neck Surg. 2017 Jun 10;46(1):45 - PubMed
  5. JAMA Oncol. 2017 Apr 1;3(4):524-548 - PubMed
  6. Chin J Cancer. 2013 Nov;32(11):614-8 - PubMed
  7. Ann Surg Oncol. 2014 Jun;21(6):1912-8 - PubMed
  8. Am J Surg. 1994 Nov;168(5):494-8 - PubMed
  9. Mayo Clin Proc. 2016 Mar;91(3):386-96 - PubMed
  10. F1000Prime Rep. 2014 Jun 02;6:44 - PubMed
  11. Gastric Cancer. 2014 Jan;17(1):67-75 - PubMed
  12. Eur Arch Otorhinolaryngol. 2018 Feb;275(2):515-524 - PubMed
  13. J Urol. 2007 Apr;177(4):1273-5; discussion 1275-6 - PubMed
  14. Radiat Oncol. 2015 Aug 25;10:181 - PubMed
  15. Annu Rev Pathol. 2009;4:49-70 - PubMed
  16. PLoS One. 2013;8(2):e56613 - PubMed
  17. Oral Oncol. 2012 Apr;48(4):329-36 - PubMed
  18. CA Cancer J Clin. 2017 Mar;67(2):122-137 - PubMed
  19. Virchows Arch. 2016 Dec;469(6):635-641 - PubMed
  20. Head Neck. 2009 Nov;31(11):1482-8 - PubMed
  21. Curr Treat Options Oncol. 2012 Mar;13(1):35-46 - PubMed
  22. Cancer. 2016 Feb 15;122(4):534-45 - PubMed
  23. Cancer. 2016 May 1;122(9):1388-97 - PubMed
  24. Am J Surg. 2016 Aug;212(2):251-7 - PubMed
  25. Asian Pac J Cancer Prev. 2013;14(9):5219-23 - PubMed
  26. Cancer. 2009 Dec 15;115(24):5700-10 - PubMed
  27. Am J Otolaryngol. 2017 Sep - Oct;38(5):529-532 - PubMed
  28. Sci Rep. 2017 Jul 27;7(1):6708 - PubMed
  29. World J Surg. 2007 Nov;31(11):2184-91 - PubMed
  30. Cancer Imaging. 2014 Apr 28;14:15 - PubMed

Publication Types